<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01989130</url>
  </required_header>
  <id_info>
    <org_study_id>071346</org_study_id>
    <nct_id>NCT01989130</nct_id>
  </id_info>
  <brief_title>Evaluation of Immediate v. Delayed CT/NG Test for Treatment in the ED</brief_title>
  <official_title>Evaluation of the Cepheid Xpert CT/NG For Management of STI in the ED: Immediate V. Delayed Test Results</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cepheid</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>George Washington University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if immediate availability of GeneXpertÂ® CT/NG test
      results reduces the overtreatment rate for ED patients with suspected gonorrhea or chlamydia
      and to assess changes in clinician management decisions with real-time test results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct a randomized controlled trial in patients aged 18 and older
      where the treating clinician is ordering a CT/NG test. Clinicians will be approached by a
      research assistant while they are in the ED and asked whether a CT/NG swab will be ordered
      and if CT/NG is in the differential diagnosis. Then, potentially eligible patients will be
      approached and asked for consent to enroll. For patients that consent, simple randomization
      procedure (i.e. random number generator) will be used to assign patients to either immediate
      test results or delayed test results. Typically, in the ED these tests are ordered for
      diagnostic rather than screening purposes (symptoms of vaginal discharge, abdominal pain,
      etc). Patients will be randomized to batched testing with the Roche AMPLICOR CT/NG (standard
      of care, control group) or immediate testing of clinical specimens with Cepheid CT/NG with
      real-time result reporting (within 90 minutes) to the treating clinician in the ED. Patient
      interview and clinician survey will be conducted to ascertain perceptions of illness and the
      test. A follow up interview will be conducted with the patient to determine clinical and
      public health outcomes.

      A validation of the Cepheid CT/NG test will be conducted against the hospital standard of
      care on &lt;/= 40 pilot participants. Pilot participants will be asked to provide 2 endocervical
      swabs and a urine specimen. All surveys and interviews will be conducted on pilot patients.

      While many outcomes can be measured in this study, the investigators will power this study to
      reduce the overtreatment rate with antibiotics. Assuming a baseline overtreatment rate of 88%
      (# treated with antibiotics/# without disease), to reduce this rate by 50% (to 44%), at a
      power of 80% and alpha of 0.05, the investigators will need to enroll 42 patients (21
      controls and 21 study patients) with negative tests. Given an estimated positive rate of 6%,
      and that approximately 50% of patients who receive these tests for any reason will be treated
      empirically with antibiotics, the investigators think that enrolling a total of 70 patients
      with full data (enrollment survey, clinician survey, and follow up survey) would be
      sufficient to identify trends with this subject matter. Due to the sensitive nature of the
      subject matter and the high percentages of lost-to-follow up with ED patients, the
      investigators estimate approximately 50% will have incomplete data. Therefore, the
      investigators request to enroll 150 patients in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Prescribed Antibiotic Treatment</measure>
    <time_frame>one year</time_frame>
    <description>Measurement of the number and type of antibiotics prescribed to CT/NG + v. CT/NG - in both groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Utilization</measure>
    <time_frame>one year</time_frame>
    <description>Quantify the number of visits to healthcare facilities/providers and non-ED related medications purchased in 7-10 days after enrollment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Healthcare Cost</measure>
    <time_frame>one year</time_frame>
    <description>To quantify the amount billed to insurance companies and out of pocket expenses for initial encounter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resolution of Symptoms</measure>
    <time_frame>one year</time_frame>
    <description>Number of patients that report having no symptoms 7 to 10 days after initial encounter</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Reproductive Tract Infections</condition>
  <arm_group>
    <arm_group_label>Real-time results with Cepheid Xpert CT/NG Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diagnosis of +/- CT/NG within 2 hours of specimen entering laboratory</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Batched results with Roche AMPLICOR CT/NG test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diagnosis of +/- CT/NG within 1 to 4 days of visit to the ED</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Roche AMPLICOR CT/NG</intervention_name>
    <arm_group_label>Batched results with Roche AMPLICOR CT/NG test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cepheid Xpert CT/NG Test</intervention_name>
    <arm_group_label>Real-time results with Cepheid Xpert CT/NG Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  greater than 18 years

          -  clinical suspicion of CT/NG

          -  able to give informed consent

          -  willingness to wait for test result

        Exclusion Criteria:

          -  less than 18 years

          -  pregnancy

          -  prisoners

          -  unable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larissa May, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The George Washington University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Andric B, Drowos J, Trepka MJ, Suciu G, Alonso A, Hennekens CH. High frequencies of negative pretreatment results following presumptive antibiotic treatment for chlamydia and gonorrhea. South Med J. 2013 May;106(5):321-6. doi: 10.1097/SMJ.0b013e318291b3c2.</citation>
    <PMID>23644641</PMID>
  </reference>
  <reference>
    <citation>Levitt MA, Johnson S, Engelstad L, Montana R, Stewart S. Clinical management of chlamydia and gonorrhea infection in a county teaching emergency department--concerns in overtreatment, undertreatment, and follow-up treatment success. J Emerg Med. 2003 Jul;25(1):7-11.</citation>
    <PMID>12865101</PMID>
  </reference>
  <reference>
    <citation>Gaydos CA, Van Der Pol B, Jett-Goheen M, Barnes M, Quinn N, Clark C, Daniel GE, Dixon PB, Hook EW 3rd; CT/NG Study Group. Performance of the Cepheid CT/NG Xpert Rapid PCR Test for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol. 2013 Jun;51(6):1666-72. doi: 10.1128/JCM.03461-12. Epub 2013 Mar 6.</citation>
    <PMID>23467600</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2013</study_first_submitted>
  <study_first_submitted_qc>November 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2013</study_first_posted>
  <results_first_submitted>February 23, 2016</results_first_submitted>
  <results_first_submitted_qc>March 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2017</results_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antimicrobial stewardship</keyword>
  <keyword>Cepheid Xpert CT/NG</keyword>
  <keyword>chlamydia</keyword>
  <keyword>gonorrhea</keyword>
  <keyword>emergency department</keyword>
  <keyword>Diagnostic Techniques, Obstetrical and Gynecological</keyword>
  <keyword>Diagnostic Techniques, Urological</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reproductive Tract Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Real-time Results With Cepheid Xpert CT/NG Test</title>
          <description>Diagnosis of +/- CT/NG within 2 hours of specimen entering laboratory
Cepheid Xpert CT/NG Test</description>
        </group>
        <group group_id="P2">
          <title>Batched Results With Roche AMPLICOR CT/NG Test</title>
          <description>Diagnosis of +/- CT/NG within 1 to 4 days of visit to the ED
Roche AMPLICOR CT/NG</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Real-time Results With Cepheid Xpert CT/NG Test</title>
          <description>Diagnosis of +/- CT/NG within 2 hours of specimen entering laboratory
Cepheid Xpert CT/NG Test</description>
        </group>
        <group group_id="B2">
          <title>Batched Results With Roche AMPLICOR CT/NG Test</title>
          <description>Diagnosis of +/- CT/NG within 1 to 4 days of visit to the ED
Roche AMPLICOR CT/NG</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Prescribed Antibiotic Treatment</title>
        <description>Measurement of the number and type of antibiotics prescribed to CT/NG + v. CT/NG - in both groups</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Real-time Results With Cepheid Xpert CT/NG Test</title>
            <description>Diagnosis of +/- CT/NG within 2 hours of specimen entering laboratory
Cepheid Xpert CT/NG Test</description>
          </group>
          <group group_id="O2">
            <title>Batched Results With Roche AMPLICOR CT/NG Test</title>
            <description>Diagnosis of +/- CT/NG within 1 to 4 days of visit to the ED
Roche AMPLICOR CT/NG</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Prescribed Antibiotic Treatment</title>
          <description>Measurement of the number and type of antibiotics prescribed to CT/NG + v. CT/NG - in both groups</description>
          <units>percentage of 70 participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Health Utilization</title>
        <description>Quantify the number of visits to healthcare facilities/providers and non-ED related medications purchased in 7-10 days after enrollment</description>
        <time_frame>one year</time_frame>
        <population>Analysis included patients that responded to the 7-10 day follow-up phone call.</population>
        <group_list>
          <group group_id="O1">
            <title>Real-time Results With Cepheid Xpert CT/NG Test</title>
            <description>Diagnosis of +/- CT/NG within 2 hours of specimen entering laboratory
Cepheid Xpert CT/NG Test</description>
          </group>
          <group group_id="O2">
            <title>Batched Results With Roche AMPLICOR CT/NG Test</title>
            <description>Diagnosis of +/- CT/NG within 1 to 4 days of visit to the ED
Roche AMPLICOR CT/NG</description>
          </group>
        </group_list>
        <measure>
          <title>Health Utilization</title>
          <description>Quantify the number of visits to healthcare facilities/providers and non-ED related medications purchased in 7-10 days after enrollment</description>
          <population>Analysis included patients that responded to the 7-10 day follow-up phone call.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subsequent hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>subsequent office visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>new prescription drugs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Healthcare Cost</title>
        <description>To quantify the amount billed to insurance companies and out of pocket expenses for initial encounter</description>
        <time_frame>one year</time_frame>
        <population>This outcome measure was not measured, as insurance coverage for hospital and physician charges was unavailable.</population>
        <group_list>
          <group group_id="O1">
            <title>Real-time Results With Cepheid Xpert CT/NG Test</title>
            <description>Diagnosis of +/- CT/NG within 2 hours of specimen entering laboratory
Cepheid Xpert CT/NG Test</description>
          </group>
          <group group_id="O2">
            <title>Batched Results With Roche AMPLICOR CT/NG Test</title>
            <description>Diagnosis of +/- CT/NG within 1 to 4 days of visit to the ED
Roche AMPLICOR CT/NG</description>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Cost</title>
          <description>To quantify the amount billed to insurance companies and out of pocket expenses for initial encounter</description>
          <population>This outcome measure was not measured, as insurance coverage for hospital and physician charges was unavailable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Resolution of Symptoms</title>
        <description>Number of patients that report having no symptoms 7 to 10 days after initial encounter</description>
        <time_frame>one year</time_frame>
        <population>Analysis of patients who completed the 7-10 day follow-up phone call</population>
        <group_list>
          <group group_id="O1">
            <title>Real-time Results With Cepheid Xpert CT/NG Test</title>
            <description>Diagnosis of +/- CT/NG within 2 hours of specimen entering laboratory
Cepheid Xpert CT/NG Test</description>
          </group>
          <group group_id="O2">
            <title>Batched Results With Roche AMPLICOR CT/NG Test</title>
            <description>Diagnosis of +/- CT/NG within 1 to 4 days of visit to the ED
Roche AMPLICOR CT/NG</description>
          </group>
        </group_list>
        <measure>
          <title>Resolution of Symptoms</title>
          <description>Number of patients that report having no symptoms 7 to 10 days after initial encounter</description>
          <population>Analysis of patients who completed the 7-10 day follow-up phone call</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Real-time Results With Cepheid Xpert CT/NG Test</title>
          <description>Diagnosis of +/- CT/NG within 2 hours of specimen entering laboratory
Cepheid Xpert CT/NG Test</description>
        </group>
        <group group_id="E2">
          <title>Batched Results With Roche AMPLICOR CT/NG Test</title>
          <description>Diagnosis of +/- CT/NG within 1 to 4 days of visit to the ED
Roche AMPLICOR CT/NG</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Larissa May, MD</name_or_title>
      <organization>University of California-Davis</organization>
      <phone>916-736-5010</phone>
      <email>lsmay@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

